The CRO focuses its services towards biotechs by stating that they are cheaper and more efficient compared to rivals, and it was this principle that drew in General Catalyst to provide investment.
Leveraging Eurofins’ pharmacology, in-vitro models and ADME capabilities, PharmaResources aims to accelerate drug discovery for its clients in small molecule drug R&D.
A fellowship program run by Worldwide Clinical Trials aims to equip scientists with the skills to meet industry demands for ‘informed, differentiated’ services.
It’s a lot more complicated than a simple technology – says Iqvia global head of virtual trials, who shares four lessons learned during a discussion at the company’s headquarters in Research Triangle Park.
Clinical trials are less safe today as researchers are inundated with increasing amounts of data and new processes developed in part by CROs, which have created “tier upon tier of bureaucracy,” argues industry expert, who warns that things are getting...
CTI expects to create up to 50 new jobs over the next several years in response to significant growth in the pharma and biotech industry, specifically in cell and gene therapies, says CEO.
Amsbio is adding experimental cell lines to its CAR-T cell services to meet an increasing demand for the technology, according to the UK-based provider.
The MI-based CRO MMS Holdings is among the team at the Health Analytics Collective, a research group hoping to reduce the need for new clinical trials by using readily available data – and an MIT-incubated programming language.
August Research is adding clinical trial operations in Georgia and Moldova, expanding the CRO’s reach in Central and Eastern Europe – a less developed market with “fewer competitive trials and lower costs,” says CEO.
Biorasi plans to scale several aspects of its global CRO business following a PE investment – and while it does not plan to “buy size,” smaller strategic acquisitions are not out of the question, says company executive.
PPD is adding nearly 6,000 square feet of new lab space – and about 20 employees – dedicated to gene and cell therapy analytical testing at its site in Athlone, Ireland.
The Asia-Pacific CRO Novotech has grown its operations in South Korea, a market that has seen greater interest from North American and European companies, says exec.
Catalent’s existing clinical packaging facility in Shanghai is nearing the end of its expansion, ready to meet the needs of the growing Asia-Pacific region.
QPS has expanded its Phase I clinical trial capabilities by more than 20% and doubled its lab space, which will allow the CRO to accommodate ‘exponentially more sponsors’ as demand continues to increase.
The PE firm Ampersand Capital Partners has acquired Pacific Biomarkers and is merging the CRO with Neomed-Labs to streamline clinical immunology development.
The Nuvisan Group is taking on part of Galderma’s R&D capacities site, growing its service lines in bioanalysis, clinical trial supplies, and pharmaceutical analytics
IRBM and Merck have signed a new agreement in the peptide therapeutics area through which the Italian CRO will identify potential peptide leads for a specific Merck target.
The outsourced service providers have signed a new collaboration agreement to provide global pharmaceutical and biotechnology clients access to electrophysiology and ion channel screening.
Repeal of the hotly debated medical device tax would free up research and development resources and bring clinical trials back to the US, say CRO industry executives.
Accelovance and Linical merged in March of this year to create a global midsized CRO for which ‘future possibilities are endless,’ says newly appointed CEO.
WCG’s acquisition of KMR Group and MCC addresses sponsor and CRO need to establish a common set of metrics to understand and manage clinical trial performance, says CEO.
The industry needs “to strike a balance” between science and feasible execution as increasingly complex clinical trial protocols are impeding efficiency and driving up costs, says industry expert.
PPD has expanded its central lab technology capabilities with the launch of a new client portal and a companion application for its Preclarus investigator site portal.
Synteract has acquired the dermatology CRO Cu-Tech, opening a fifth center of development as part of its strategy to develop “highly-expert therapeutic areas of focus,” says CCO.
The opening of a New York office will help communicate Clintec’s global reach to US Pharmaceutical according to new associate director of US business operations, Susan Pavone.
Novotech says its new “management hub” in Kuala Lumpur, Malaysia will serve as a base for expansion in the booming Asia-Pacific contract research sector.
US non-clinical contract research firm Wil Research Laboratories has reduced its 700 strong workforce by 4 per cent, citing a drop in business due to the global economic downturn as the basis for the cuts.
With M&A activity dominating Big Pharma's agenda at the moment, the contract research market is having to evolve and adapt to the turbulent environmnet. Outsourcing-pharma asked Frost & Sullivan analyst Barath Shankar to offer his opinion...
in-PharmaTechnologist.com presents its round up of the latest developments in contract research, including CTI partnering to access Latin America, Encorium signing contracts worth $13.5m and Omnicare setting up in Sweden.
India's budget finance minister has today announced a tax exemption
on all services carried out by its contract research and clinical
trials industry – a saving of 12.24 per cent.
Preclinical and early-phase drug discovery will be the next service
area to take off in India, Dr. Reddy's CEO GV Prasa predicted at a
conference yesterday.
